OPUVIZ, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen's second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency IN ...

Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...

OPUVIZ™, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen’s second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency ...

OPUVIZ has been recommended for approval in adult patients for the treatment of neovascular age related macular degeneration, visual impairment due to macular oedema secondary to retinal vein ...

Cystoid macular edema risk is lower for those using prostaglandin analogs than those using any other common class of glaucoma topical.

Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...

A total of 134 subjects with MacTel that had at least two visits with OCT scans were collected. 14 subjects were excluded due ...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

The National Institute for Health and Care Excellence (NICE) has recommended access Vabysmo (faricimab) for the treatment of ...

The authors concluded that the switch from aflibercept biosimilar ranibizumab in patients with nAMD demonstrated efficacy in ...

Both are considered interchangeable with the reference drug ranibizumab (Lucentis, Genentech). Byooviz was approved to treat wet age-related macular degeneration, macular edema associated with retinal ...

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Hold rating on Alimera (ALIM – Research Report). The ...